Recent Clinical Trials of Cholinomimetics for Patients with Alzheimer’s Disease in Japan

  • Akira Homma
  • Kazuo Hasegawa
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)


According to the estimation based on the recent epidemiological investigations of age-associated dementia conducted in Japan (Otsuka et al., 1991), an overall prevalence rate of dementia including institutionalized elderly persons and admitted patients in the population aged 65 years and over was 6.7% in 1990. The number of those with dementia was approximately 994,000. Also, it has been reported that vascular dementia (VD) were more predominant than Alzheimer type dementia (ATD) in Japan (Homma and Hasegawa, 1989). However, Karasawa and Homma (1990) suggested a relatively increased prevalence rate of ATD and a decreased rate of VD probably due to the reduction of cerebrovascular disorders in the elderly persons in survey results conducted in Tokyo in 1980 and 1988. It seems no doubt that ATD will be the most common age-associated dementia in the elderly in Japan. Taking into consideration an extraordinary burden on patients, caregivers and society, effective treatments for ATD patients are urgently required.


Vascular Dementia Emotional Function Clinical Laboratory Test Normal Pressure Hydrocephalus Behavior Rating Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Dahlke, F., Lohaus, A., and Gutzman, H., 1992, Reliability and clinical concepts underlying global judgements in dementia: Implications for clinical research, Psydwpharmacol. Bull. 28: 425.Google Scholar
  2. Davis, K.L. and Mohs, R.C., 1982, Enhancement of memory processes in Alzheimer’s disease with multiple-dose intravenous physostigmine, Am. J. Psychiatry 139: 1241.Google Scholar
  3. Davis, K.L., Thal, L.J., Gamzu, E.R., Davis, C.S., Woolson, R.F., Gracon, S.I., Drachman, D.A., Schneider L.S., Whitehouse, P.J., Hoover, T.M., Moms, J.C., Kawas, C.H., Knopman, D.S., Earl, N.L., Kumar, V., Doody, R.S., and the Tacrine collaborative study group, 1992, N. Eng. J. Med. 327: 1253.Google Scholar
  4. Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowsky, C.H., and Dolan-Ureno, 1992, A controlled trial of Tacrine in Alzheimer’s disease, JAMA 268: 2523.PubMedCrossRefGoogle Scholar
  5. Folstein, M.F., Folstein, S.E., and McHugh, P.R., 1975, Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res. 12: 189.PubMedCrossRefGoogle Scholar
  6. Gottfries, C.G., Brane, G., and Steen G., 1982, A new rating scale for dementia syndromes, Gerontology 28, suppl 2: 20.Google Scholar
  7. Hachinski, V.C., Iluff, L.D., Zilhka, E., du Boulay, G.H., McAllister, V.L., Marshall, J., Ross Russell, R.W., and Symon L., 1975, Cerebral blood flow in dementia, Arch. Neurol. 32: 632.PubMedCrossRefGoogle Scholar
  8. Hasegawa, K., Inoue, K., and Moriya, K., 1974, an investigation of dementia rating scale for the elderly, Clin. Psychiatry 16: 33. (in Japanese)Google Scholar
  9. Homma, A., and Hasegawa, K., 1989, Recent developments in gerontopsychiatric research on age-associated dementia in Japan, IN. Psychogeriatr. 1: 31.CrossRefGoogle Scholar
  10. Homma, A., Mina, R., Ishii, T., and Hasegawa, K., 1991, Jap. J. Geriatr. Psychiatry 2:1217. (in Japanese) Homma, A., Fukusawa, K., Tsukada, Y., Ishii, T., Hasegawa, K., and Mohs, R.C., 1992, Jap. J. Geriatr. Psychiatry 3: 647. (in Japanese)Google Scholar
  11. Karasawa, A., and Homma, A., 1990, Recent changes in the prevalence of dementia in the Tokyo metropolis, in: “Psychogeriatrics: Biomedical and Social Advances, K. Hasegawa and A. Homma, eds, Excerpts Medica, Tokyo.Google Scholar
  12. Kobayashi, T., Hariguchi, S., Nishimura, T., Takeda, M., Fukunaga T., Inoue, O., Tanaka, S., Kondo, S., and Shinkawa, H., 1988, A new clinical scale for rating of mental states and activities of daily living of the elderly, Jap. J. Clin. Psychiatry 17: 1653. (in Japanese)Google Scholar
  13. Kramer-Ginsberg, E., Mohs, R.C., Aryan, M., Lobel, D., Silverman, J., Davidson, M., Davis, K.L., 1988, Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report, Psychophannacol. Bull. 24: 45 8.Google Scholar
  14. Kurihara, H., 1986, Effects of amiridine on ambulatory activity and discrete shuttle avoidance response in mice, Folla Phannacnl. Japon. 88: 299.CrossRefGoogle Scholar
  15. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E., 1986, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Departrment of Health and Human Services task force on Alzheimer’s disease, Neurology 34: 939.CrossRefGoogle Scholar
  16. Nabeshima, T., Yoshida, S., and Kameyama, T., 1988, Effects of the novel compound NIK-247 on impairment of passive avoidance response in mice, Eur. J. Pharmacol. 154: 263.PubMedCrossRefGoogle Scholar
  17. Otsuka, T., Karasawa, A., Matsushita, M., and Kawaguchi, Y., 1991, Study on care and care system for patients with dementia, in: “Aging and Health Research 1991, Aging and Health Research Foundation, Tokyo.Google Scholar
  18. Peripheral and Central Nervous System Drugs Advisory Committee Meetings, 1989, Department of Health and Human Services, Public Health Services, Food and Drug Administration, Rockville, MD.Google Scholar
  19. Reisberg, B., Ferris, S.H., de Leon, M.J., and Crook, T., 1982, The Global Deterioration Scale for assessment of primary degenerative dementia, Am. J. Psychiatry 139: 1136.PubMedGoogle Scholar
  20. Reisberg, B., Ferris, S.H., Anand, R., de Leon, M.J., Schneck M.K., Buttinger, C., and Borenstein J., 1984, Functional staging of dementia of the Alzheimer’s type, Ann. NY Acad. Sci. 435: 481.CrossRefGoogle Scholar
  21. Shibanoki, S., Ishii, Y., Kubo, T., Kogure, M., Asai, S., and Ichikawa, K., 1991, Effects of 9-amino2,3,5,6,7,8-hexahydro-1H-cyclopenta-(b)-quinoline monohydrate hydrochloride (NIK-247) on cholinergic enzyme activity in rats, Pharmacol. Biodom. Behay. 39: 499.CrossRefGoogle Scholar
  22. Thal, L.J., Fuld, P.A., Maser, D.M., Sharpless, N.S., 1983, Oral physostigmine and lecithin improve memory in Alzheimer’s disease, Ann. Neurot. 13: 491.CrossRefGoogle Scholar
  23. Ueki, A., and Miyoshi, K., 1989, Effects of cholinergic drugs on learning impairment in ventral globus palliduslesioned rats, J. Neurol. Sci. 90: 1.PubMedCrossRefGoogle Scholar
  24. Yamamoto, T., Ohno, M., Sugimachi, K., and Ueki, S., 1993, Discriminative stimulus properties on NIK-247 and tetrahydroaminoacridine, centrally active cholinesterase inhibitors, in rats, 1993, Pharmacol. Bioc em. Behay. 44: 769.CrossRefGoogle Scholar
  25. Yamanashi, Y., Aratri, S., Kosaka, T., Ogura, H., and Yamatsu, K., 1988, Neurochemical studies of E2020, a novel centrally acting acetylcholinesterase inhibitor, Soc. Neurosci. Abstr. 14: 59.Google Scholar
  26. Yamanashi, Y., Ogura, H., Kosaka, T., Aratri, S., Sawa, Y., and Yamatsu, K., 1991, Inhibitory action of E2020, a novel acetylcholinesterase, on cholinesterase: comparison with other inhibitors, in: “Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Pa,*inson’s Diseases 2,” T. Nagatsu, A. Fisher, and M. Yoshida, eds., Plenum Press, New York.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Akira Homma
    • 1
  • Kazuo Hasegawa
    • 2
  1. 1.Tokyo Metropolitan Institute of GerontologyUSA
  2. 2.Department of PsychiatrySt. Marianna University School of MedicineUSA

Personalised recommendations